A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Key facts
- Who runs it
- University of Oxford
- Where
- Brazil, Laos, Nepal, and Thailand4 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 3,000 people, planned
- Started
- 22 Feb 2023
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional, 11 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Oseltamivir
- Favipiravir
- Zanamivir
- Baloxavir
- Molnupiravir
- Peramivir
- Laninamivir
- Oseltamivir and Baloxavir
- Oseltamivir and Favipiravir
- Favipiravir and Baloxavir
- Record updated
- 14 April 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study
- Adults, male or female, aged 18 to 60 years at time of consent
- Early symptomatic Influenza (A or B); at least one reported symptom of influenza (including fever, history of fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea and sore throat) within 4 days (96 hours)
- Influenza positive by rapid antigen test OR a positive RT-PCR test for influenza viruses within the last 24hrs with a Ct value of <30
- Able to walk unaided and unimpeded in activities of daily living (ADLs)
- Agrees and is able to adhere to all study procedures, including availability and contact information for follow-up visits
Who cannot take part
- Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity
- Received live attenuated influenza virus vaccine within 3 weeks prior to study entry
- Presence of any chronic illness/condition requiring long term treatment or other significant comorbidity
- Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics
- Currently participating in another interventional influenza or COVID-19 therapeutic trial
- Known to be currently co-infected with SARS-CoV-2 (i.e. confirmed with positive ATK or RT-PCR)
- Clinically relevant laboratory abnormalities discovered at screening; Haemoglobin <10g/dL; Platelet count <100,000/uL; ALT > 2x ULN; Total bilirubin >1.5 x ULN; eGFR <70mls/min/1.73m2
- The patient may not enter the study if ANY of the following apply:
- BMI ≥35 Kg/m2
- For females: pregnancy, actively trying to become pregnant or lactation (healthy women on OCP are eligible to join)
- Clinical evidence of pneumonia- e.g. shortness of breath, hypoxaemia, crepitations (imaging not required)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Influenza
This trial is currently available in Brazil, Laos, Nepal, and Thailand.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other.
Read full original descriptionShow less
AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator
The 11 groups in the trial
- Oseltamivir (TAMIFLU®)Treatment being tested
Treatment: Oseltamivir
- FavipiravirTreatment being tested
- Zanamivir (RELENZA®) [Pending addition]Treatment being tested
Treatment: Zanamivir
- Baloxavir (XOFLUZA®)Treatment being tested
Treatment: Baloxavir
- Molnupiravir [Pending addition]Treatment being tested
Treatment: Molnupiravir
- Peramivir (RAPIVAB®) [Pending addition]Treatment being tested
Treatment: Peramivir
- Laninamivir (INAVIR®) [Pending addition]Treatment being tested
Treatment: Laninamivir
- Oseltamivir and Baloxavir [Pending addition]Treatment being tested
Treatment: Oseltamivir and Baloxavir
- Oseltamivir and Favipiravir [Pending addition]Treatment being tested
Treatment: Oseltamivir and Favipiravir
- Favipiravir and Baloxavir [Pending addition]Treatment being tested
Treatment: Favipiravir and Baloxavir
- Negative control groupNo study treatment, for comparison
No treatment (except antipyretics- paracetamol)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)
- Criteria questions
- Built from NCT05648448, who can take part
- Publications
- Record updated
- 14 April 2026